Can-Fite BioPharma Ltd.CANFNYSE
Loading
Operating Income Growth TrendStable
Percentile Rank46
Year-over-Year Change
Year-over-year operating income growth rate
Latest
0.00%
↑ 100% vs avg
Percentile
P46
Within normal range
Streak
1 qtr
Consecutive growthStable
Average
-9.58%
Historical baseline
| Period | Value |
|---|---|
| Q2 2025 | 0.00% |
| Q1 2025 | -21.36% |
| Q4 2024 | 0.00% |
| Q3 2024 | 1.42% |
| Q2 2024 | 0.00% |
| Q1 2024 | -11.61% |
| Q4 2023 | 1.66% |
| Q3 2023 | -4.54% |
| Q2 2023 | 34.22% |
| Q1 2023 | 12.03% |
| Q4 2022 | -19.82% |
| Q3 2022 | -24.30% |
| Q2 2022 | 17.13% |
| Q1 2022 | 37.98% |
| Q4 2021 | -14.76% |
| Q3 2021 | -12.03% |
| Q2 2021 | -44.31% |
| Q1 2021 | 38.90% |
| Q4 2020 | -43.32% |
| Q3 2020 | 35.29% |
| Q2 2020 | 10.41% |
| Q1 2020 | 7.18% |
| Q4 2019 | -65.07% |
| Q3 2019 | 3.56% |
| Q2 2019 | -69.14% |
| Q1 2019 | 31.64% |
| Q4 2018 | 61.29% |
| Q3 2018 | -228.72% |
| Q2 2018 | -23.87% |
| Q1 2018 | 33.78% |
| Q4 2017 | -105.36% |
| Q3 2017 | 37.45% |
| Q2 2017 | 3.90% |
| Q1 2017 | 25.05% |
| Q4 2016 | -14.08% |
| Q3 2016 | -7.04% |
| Q2 2016 | -28.87% |
| Q1 2016 | 30.96% |
| Q4 2015 | -77.50% |
| Q3 2015 | 8.65% |